Pages that link to "Q70920161"
Jump to navigation
Jump to search
The following pages link to Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands (Q70920161):
Displaying 50 items.
- Mammalian nicotinic acetylcholine receptors: from structure to function (Q24647069) (← links)
- Topology of ligand binding sites on the nicotinic acetylcholine receptor (Q28256897) (← links)
- Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial (Q28362149) (← links)
- Human neuronal nicotinic receptors (Q29397943) (← links)
- Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. (Q30446699) (← links)
- The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice (Q30463325) (← links)
- Molecular targets for treating cognitive dysfunction in schizophrenia. (Q30491310) (← links)
- Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors (Q30497637) (← links)
- Galantamine: a review of its use in Alzheimer's disease (Q31754077) (← links)
- Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. (Q33694502) (← links)
- Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. (Q34156343) (← links)
- Specificity determinants of allosteric modulation in the neuronal nicotinic acetylcholine receptor: a fine line between inhibition and potentiation (Q34230674) (← links)
- Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors (Q34545452) (← links)
- Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen (Q34655353) (← links)
- Methyllycaconitine- and scopolamine-induced cognitive dysfunction: differential reversal effect by cognition-enhancing drugs (Q34667088) (← links)
- Structural answers and persistent questions about how nicotinic receptors work (Q34782188) (← links)
- Nicotinic cholinergic modulation: galantamine as a prototype. (Q35025118) (← links)
- Cholinergic modulation of the cortical neuronal network (Q35104959) (← links)
- Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitations (Q35182164) (← links)
- Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease (Q35538846) (← links)
- Galantamine facilitates acquisition of hippocampus-dependent trace eyeblink conditioning in aged rabbits (Q35541457) (← links)
- The effects of postnatal alcohol exposure and galantamine on the context pre-exposure facilitation effect and acetylcholine efflux using in vivo microdialysis (Q35554418) (← links)
- Clinical pharmacokinetics of galantamine (Q35607538) (← links)
- Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy (Q35767249) (← links)
- Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists (Q35810060) (← links)
- Prediction of tissue-specific effects of gene knockout on apoptosis in different anatomical structures of human brain. (Q35875313) (← links)
- Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats (Q36174102) (← links)
- Nicotinic agonists, antagonists, and modulators from natural sources (Q36216398) (← links)
- Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors (Q36982933) (← links)
- High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia (Q37001421) (← links)
- Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease (Q37092481) (← links)
- Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration (Q37230901) (← links)
- Promising therapeutics with natural bioactive compounds for improving learning and memory--a review of randomized trials. (Q38040287) (← links)
- Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment (Q38860110) (← links)
- Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells (Q40413207) (← links)
- Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. (Q40454009) (← links)
- Activation of heteroliganded mouse muscle nicotinic receptors. (Q40457011) (← links)
- A single in vivo application of cholinesterase inhibitors has neuron type-specific effects on nicotinic receptor activity in guinea pig hippocampus (Q41897944) (← links)
- Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro (Q42728333) (← links)
- Subunit-dependent modulation of neuronal nicotinic receptors by zinc. (Q43540440) (← links)
- A nonlinear mixed effects IVIVC model for multi-release drug delivery systems. (Q46379979) (← links)
- Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach (Q46863803) (← links)
- Neuroprotective Effects of Galantamine on Nerve Agent-Induced Neuroglial and Biochemical Changes. (Q47774032) (← links)
- Post-Injury Administration of Galantamine Reduces Traumatic Brain Injury Pathology and Improves Outcome (Q47819114) (← links)
- In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile (Q48258202) (← links)
- Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice (Q48395191) (← links)
- Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia (Q51037125) (← links)
- Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy (Q58596304) (← links)
- Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors (Q88399016) (← links)
- Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies (Q89714248) (← links)